Convexia is building an AI-maximalist pharma company. We replace months of manual drug asset diligence with automated asset sourcing, in silico scientific evaluation, commercial modeling, and clinical risk analysis. These agents feed into our proprietary PoS model to identify high potential drug assets.

We sell the platform to pharma BD teams, biotech startups, and rare disease clinician teams today. As we become system-integrated with customers, we will begin owning and advancing assets ourselves through key development milestones.